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Abstract
Background: Antenatal corticosteroids are commonly used to reduce neonatal mortality, but most research to date
has been in high-resource settings and few studies have evaluated its impact on stillbirth. In the Antenatal Corticosteroids
Trial (ACT), a multi-country trial to assess impact of a multi-faceted intervention including antenatal corticosteroids to
reduce neonatal mortality associated with preterm birth, we found an overall increase in 28-day neonatal mortality and
stillbirth associated with the intervention.
Methods: The ACT was a cluster-randomized trial conducted in 102 clusters across 7 research sites in 6 countries (India
[2 sites], Pakistan, Zambia, Kenya, Guatemala and Argentina), comparing an intervention to train birth attendants at all
levels of the health system to identify women at risk of preterm birth, administer corticosteroids and refer women at risk.
Because of inadequate gestational age dating, the <5th percentile birth weight was used as a proxy for preterm birth. A
pre-specified secondary outcome of the trial was stillbirth.
Results: After adjusting for the pre-trial imbalance in stillbirth rates, the ACT intervention was associated with a
non-significant increased risk of stillbirth (aRR 1.08, 95 % CI, 0.99–1.17, p–0.073). Additionally, the stillbirth rate was
higher in the term births (1.20 95 % CI 1.06–1.37, 0.004) and among those with signs of maceration (RR 1.18 (1.04–1.35),
p = 0.013) in the intervention vs. control clusters. Differences in obstetric care favored the control clusters and maternal
infection was likely more common in the intervention clusters.
Conclusions: In this pragmatic trial, limited data were available to identify the causes of the increase in stillbirths in
the intervention clusters. A higher rate of stillbirth in the intervention clusters prior to the trial, differences in obstetric
care and an increase in maternal infection are potential explanations for the observed increase in stillbirths in the
intervention clusters during the trial.
Trial registration: clinicaltrials.gov (NCT01084096)
Background
The Antenatal Corticosteroid Trial (ACT) was a cluster
randomized trial performed in 7 sites in 6 low and middle
income countries (LMIC) [1, 2]. The primary outcomes for
that trial were to determine whether a multicomponent
intervention increased the administration of antenatal
corticosteroids (ACS) in the women at risk of preterm
birth and then reduced neonatal mortality among that
group. The primary outcome of neonatal mortality out-
come was assessed among infants born at less than the
site specific 5th percentile birth weight and was used as
a surrogate measure for preterm birth. The intervention in-
creased ACS use in the treatment clusters (46 % vs.10 % in
<5th percentile births), but being in the intervention clusters
was not associated with an improvement in neonatal mor-
tality in the < 5th percentile infants [1]. An unexpected find-
ing was that neonatal mortality was higher overall in the
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intervention clusters, with the excess mortality occurring in
infants born at ≥25th percentile site-specific birth weight.
A pre-specified secondary outcome was the stillbirth rate,
which was higher in the intervention clusters compared to
the control clusters [2]. In this paper, we explore potential
mechanisms which might have resulted in the higher still-
birth rate in the intervention clusters. Of note, ACT was a
“pragmatic” trial and not designed to evaluate mechanisms
leading to specific pregnancy outcomes, especially those
such as stillbirth that were not a primary endpoint. We also
emphasize that compared to prior trials demonstrating
efficacy of ACS which were all individually randomized and
conducted in in high and some middle income country
hospitals with good obstetric and neonatal care, this cluster
randomized trial enrolled more than 100,000 subjects in
countries where half the women delivered at home or in
low-level community clinics [3, 4].
The hospitals in these areas rarely provided comprehen-
sive obstetric or intensive newborn services and rarely
monitored the fetuses during labor [5]. During the time
that ACT was initiated, ultrasound gestational age dating
was generally unavailable for women in these sites. For that
reason, the target group for the primary neonatal outcome
was not determined by gestational age, but by a birth
weight < 5th percentile for babies born at that site. Because
placental examinations and autopsies were not available,
little data are available to assess the causes of the stillbirths.
Nevertheless, because of the unexpected excess of stillbirths
in the intervention compared to the control clusters during
the ACT trial, we used available data to explore potential
reasons for the higher rate of stillbirths in the intervention
clusters.
Methods
This is a secondary analysis of data collected during the
ACT study focusing on stillbirths. A stillbirth was de-
fined as a baby born at ≥500 g or an estimated 20 weeks
gestational age without a heartbeat, respirations or signs
of movement [6]. ACT was a cluster-randomized trial
undertaken in specified geographic clusters each with
approximately 500 births per year in sites in Argentina,
Guatemala, Kenya, Zambia, Pakistan, and in Belgaum
and Nagpur, India. The study intervention and methods are
described in detail elsewhere [1]. In brief, the study clusters
were defined by each site and then randomized by the data
center, RTI International (RTI). To randomize clusters, RTI
created strata based on the study site and neonatal mortal-
ity rates using an ongoing registry; however the stillbirth
rates in the individual clusters were not compared prior to
the trial nor considered in the randomization process.
The ACT outcome data were collected independently
of the intervention team by trained registry adminis-
trators (RAs) in a prospective maternal and newborn
health (MNH) registry, which registered pregnant women
residing within the study clusters and recorded their out-
comes. These included all deliveries, regardless of location
in home, clinic or hospital. In addition, in the ACT inter-
vention clusters, trained staff at each site collected process
data on the use of ACS. The study was overseen by a re-
search team at each of the study sites and a central study
steering committee.
All health providers in intervention clusters were
trained to identify women presenting before 36 weeks’
gestation with signs of labor, preterm premature rupture
of membranes, pre-eclampsia or eclampsia, and obstetric
hemorrhage as at high risk of preterm birth and poten-
tial candidates for ACS. Providers were trained to assess
gestational age by use of an algorithm that included last
menstrual period (LMP) and estimated delivery date, or
uterine height if neither the LMP nor estimated delivery
date were known. Uterine height was measured using a
color-coded tape that was developed and validated to
measure uterine height, with a red zone indicating an
estimated gestational age younger than 36 weeks and
0 days [7]. Ultrasound was considered to be the best es-
timate for gestational age determination, but was rarely
available. Posters were displayed at facilities in the inter-
vention group and discs were designed and distributed
to calculate gestational age on the basis of LMP or esti-
mated delivery date. The posters, discs and tapes also
served as reminders about signs of risk. This gestational
age assessment was used to determine if a woman was
at high risk for preterm birth. For women determined to
be eligible, providers were trained to provide one course
of ACS (dexamethasone).
For intervention and control clusters, stillbirths were
classified as <5th percentile based on measured birth weight
and estimated weights by clinical assessment when mea-
sured weights were missing being less than the site-specific
cut off. Those without any measure of birth weight were
coded as <5th percentile. Additionally, site-specific birth
weight percentile bands and broad birth weight groups
were determined from measured and estimated birth
weights collected by the RAs. If a stillbirth did not have a
measured weight, estimated weights were used when they
fit in one of the percentile bands or otherwise was recorded
as missing. Preterm delivery (<37 weeks vs ≥ 37 weeks) was
determined by an algorithm which used the estimated de-
livery date and last menstrual period recorded by the RAs,
and site-specific 95th percentile for birth weight at
36 weeks.
Stillbirths in low-income countries are often classified
by maceration or fresh status [6]. The RAs were trained to
determine maceration status using pictures of macerated
stillbirths (e.g., peeling skin) in training sessions. Fresh
stillbirths are generally considered to have occurred within
12 h of delivery and generally during the intrapartum
period. Most of these deaths are believed to be due to
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asphyxia occurring during labor. Macerated stillbirths are
generally considered to have died before labor [8]. The
deaths in macerated fetuses are considered due to a var-
iety of causes including infection [9].
In the analysis phase, suspected maternal infection
was assessed by using a composite of process outcomes
including maternal receipt of antibiotics plus hospital
admission or referral, and receipt of intravenous fluids,
surgery, or other treatment related to infection [2]. Add-
itionally, women with postpartum signs and symptoms
of severe sepsis with admission to hospital or sepsis as
the primary cause of maternal death were included. The
definition also included evidence of antepartum or post-
partum infection for mothers with infants with a birth
weight less than 2500 g. This algorithm was not used
clinically.
The trial population included all births, whether still-
born or live born. The trial period included births between
October 2011 and March 2014, depending on each site’s
18-month enrollment period, with most births occurring
in 2012 and 2013. Because the MNH registry was initiated
prior to the trial, stillbirth rates and process data were
available in each cluster for at least a year prior to the
initiation of the study [10]. The pretrial period occurred in
2010 and 2011 (four clusters in Belgaum, India were
added in 2011).
Statistical analyses
Generalized linear models were used to evaluate the rela-
tionship between covariates and the outcomes of interest
and to develop point and interval estimates of relative risk
(RR) associated with these risk factors. Generalized esti-
mating equations were used to account for the correlation
of outcomes within cluster to develop appropriate confi-
dence intervals. Models were log binomial when possible,
otherwise Poisson models were utilized. Models were
adjusted for randomization strata. All analyses were done
by RTI International with SAS versions 9.3 and 9.4 (SAS
Institute, Cary, NC, USA).
Ethical approval
The ACT trial was reviewed and approved by the ethics
committees at each site, the World Health Organization
and the NICHD. All women provided informed consent
prior to participation. Trial registration was at clinical-
trials.gov (NCT01084096).
Results
We previously reported the stillbirth rates in the interven-
tion and control arms of the study [2]. Overall, there were a
total of 48,219 women and 48,698 babies in the ACT inter-
vention clusters and 51,523 women and 52,007 babies in
the control clusters. There were a total of 1,304 stillbirths
in the treatment clusters (26.8 per 1000 births) vs 1,264 in
the control clusters (24.3 per 1000 births) with (RR 1.11,
95 % CI 1.02–1.22, p = 0.0181) (Table 1) Using similar
registry data for the period prior to the trial (2010), the
stillbirth rate was 31.8 per 1000 births in the intervention
clusters and 27.6 per 1000 births in the control clusters (RR
1.17, 95 % CI 1.06,1.29, p = 0.0026). When we adjusted for
the pretrial stillbirth rate and randomization strata, the risk
of stillbirth during the trial period associated with being in
the intervention clusters decreased from 1.11 to 1.08 (95 %
CI, 0.99–1.17, p =0.073). Thus, the results were in the same
direction but no longer statistically significant.
Prior to the trial, the stillbirth rate in the <5th percent-
ile births was 310.6 per 1000 in the intervention group
and 272.6 per 1000 births in the control group (RR 1.15,
95 % CI 1.04–1.28, p = 0.008) (Table 1). During the trial,
the stillbirth rate in the intervention clusters in the <5th
percentile births was 228.9/1000 births while in the < 5th
percentile births in the control clusters, the stillbirth
rate was 246.6/1000 births (RR 0.99, 95 % CI 0.90–1.09,
p = 0.813). Adjusting for the pretrial stillbirth rate and
randomization strata, the stillbirth risk among the <5th
percentile births remained similar (RR 0.97, 95 % CI
0.89–1.05, p = 0.409).
We evaluated the stillbirth rates between the interven-
tion and control groups by site in the pretrial and trial
periods. As shown in Table 1, the stillbirth rates fell sub-
stantially in all sites but Kenya from the pretrial to the
trial period. The overall reductions in stillbirth rates
were by 5.0/1,000 births in the intervention clusters and
3.3/1,000 births in the control clusters. During the trial
period, 5 of the 7 sites including Pakistan, Belgaum,
Zambia, Kenya and Guatemala had a higher stillbirth rate
in the intervention compared to the control clusters, while
Nagpur and Argentina had lower stillbirth rates in the
intervention clusters. The higher stillbirth rates in the
intervention clusters in Pakistan (49.7 vs. 42.2 per 1000, p
= 0.009) and in Zambia (22.9 vs.15.9 per 1000, p = 0.020)
were statistically significant as was the lower stillbirth rate
in the intervention clusters compared to the control clus-
ters in Argentina (11.8 vs. 13.4 per 1000, p = 0.006). In the
<5th percentile births, Zambia had a higher stillbirth rate
in the intervention clusters that was nearly significant
(238.5 vs. 193.9 per 1000, p = 0.0561 while Kenya had a
lower stillbirth rate in the intervention clusters that also
was nearly significant (184.0 vs 250.0 per 1000, p = 0.066).
We next explored whether there were differences be-
tween stillbirth rates by sex in the intervention compared
to the control clusters. There were 667 male stillbirths in
the intervention clusters with a rate of 26.6 per 1000 births
and 672 stillbirth males in the control clusters for a rate of
25.0 per/1000 births (Table 2). There were 561 female still-
births in the intervention clusters (23.8 per 1000) and 540
female stillbirths for a rate of 21.6 per 1000 births in the
control clusters. Therefore, the stillbirth rates were higher
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Table 1 Stillbirth rates during the pretrial (2010) and trial periods by ACT intervention group and site
Pretrial period
Argentina Guatemala Pakistan Belgaum Nagpur Kenya Zambia Total
Characteristica Int Cntl Int Cntl Int Cntl Int Cntl Int Cntl Int Cntl Int Cntl Int Cntl RR (95 %)b p-value










































































1.15 (1.04, 1.28) 0.008
Trial period
Argentina Guatemala Pakistan Belgaum Nagpur Kenya Zambia Total
Characteristica Int Cntl Int Cntl Int Cntl Int Cntl Int Cntl Int Cntl Int Cntl Int Cntl RR (95 %)b p-value














































































Adjusted for pretrial <5th
percentile for weight SB rate
0.97 (0.89, 1.05)
0.409
aThe trial period included births between October 2011 and March 2014, depending on each site’s 18-month enrollment period, with most births occurring in 2012 and 2013. Most births included in the pretrial period
occurred in 2010. However, for the four clusters in Belgaum, India which were added after 2010, births from May 2011-May 2012 were included. Stillbirths are ≥ 20 weeks gestational age or ≥ 500 g. The denominator
for the stillbirth rate is stillbirths + live births
bGeneralized linear models were used to evaluate the relationship between covariates and the outcomes of interest and to develop point and interval estimates of relative risk (RR) associated with these risk factors.
Generalized estimating equations were used to account for the correlation of outcomes within cluster to develop appropriate confidence intervals. Models were log binomial when possible, otherwise Poisson models












in male infants and the differences in stillbirth rates be-
tween male and female fetuses were similar in the interven-
tion and control clusters.
Table 2 also provides the birth weight percentile and birth
weight group distributions in the intervention and control
clusters among the stillbirths. Site specific birth weight
percentile bands could not be categorized for 244 (19 %) of
intervention babies and 250 (20 %) of control babies. Still-
births in the treatment and control groups were similarly
distributed in the 25th - 49th and 50th – 74th birth weight
percentile bands. Among the intervention group there were
more stillbirths in the 5th - 24th percentile band and the
75th or greater percentile band than the control group.
However, when adjusted by randomization strata, these
differences in the distribution by treatment group were not
statistically significant (p = 0.2114). There were fewer still-
births missing from the broad birth weight groups (3 % of
the intervention and 4 % of the control stillbirths did not
have a measured or estimated birth weight). When com-
pared to the control group, the intervention cluster still-
birth rates were lower, but not significantly so, in the
<1000 g (p = 0.2385) and 1,500-2,499 g (p = 0.2177) groups
Table 2 Stillbirth characteristics by ACT intervention group
RR (95 % CI)d p-value
Characteristic a Intervention Control
Babies, N 48,698 52,007 – –
Stillbirths (SB), N 1,304 1,264 – –
Male SB rate, N (Rate/1000) 667 (26.6) 672 (25.0) 1.10 (0.99, 1.22) 0.086d
Female SB rate, N (Rate/1000) 561 (23.8) 540 (21.6) 1.08 (0.96, 1.22) 0.177d
Birth weight percentile b, N
(% of stillbirths)
1,060 1,014 0.211e
< 5th 601 (56.7) 612 (60.4)
5–24 161 (15.2) 139 (13.7)
25–49 110 (10.4) 102 (10.1)
50–74 83 (7.8) 74 (7.3)
75+ 105 (9.9) 87 (8.6)
Birth weight categorizedc, N 1,259 1,218
< 1000 g SB rate, N (Rate/1000) 161 (631.4) 197 (693.7) 0.93 (0.83, 1.05) 0.239d
1000–1499 g SB rate, N (Rate/1000) 272 (443.0) 215 (378.5) 1.22 (1.10, 1.36) 0.0003d
1500–2499 g SB rate, N (Rate/1000) 360 (51.6) 365 (57.4) 0.91 (0.78, 1.06) 0.218d
2500+ g SB rate, N (Rate/1000) 466 (11.4) 441 (9.9) 1.18 (1.04, 1.33) 0.008d
Preterm SB rate, N (Rate/1000) 645 (116.6) 681 (127.8) 0.93 (0.83, 1.04) 0.182d
Term SB rate, N (Rate/1000) 535 (12.8) 477 (10.6) 1.20 (1.06,1.37) 0.004d
Macerated, N (% of stillbirths) 467 (35.8) 385 (30.5) 1.18 (1.04, 1.35) 0.013f
Women in the treatment group
identified by the intervention as
high risk who received steroids
and delivered a stillborn baby
Time since 1st dose to delivery, N (%) 271
Less Than 2 Days 83 (30.6)
2–7 Days 53 (19.6)
8–30 Days 61 (22.5)
More than one month 74 (27.3)
aStillbirth ≥ 20 weeks GA or ≥ 500 g. The denominator for the stillbirth rate is stillbirths + live births
bSite-specific birth weight percentile (measured and estimated weights combined)
cBirth weight groups (measured and estimated weights combined)
dGeneralized linear models were used to evaluate the relationship between ACT intervention group and stillbirth and to develop point and interval estimates of
relative risk (RR) associated with these risk factors. Generalized estimating equations were used to account for the correlation of outcomes within cluster to
develop appropriate confidence intervals. Models were log binomial when possible, otherwise Poisson models were utilized. Models were adjusted for
randomization strata
eMantle Hansel chi-square test of ACT intervention group by birth weight percentile band adjusted for randomization strata
fGeneralized linear model was used to evaluate the relationship between ACT intervention group and maceration among stillbirths and to develop point and
interval estimates of relative risk (RR) associated with these risk factors. Generalized estimating equations were used to account for the correlation of outcomes
within cluster to develop appropriate confidence intervals. Model was log binomial and was adjusted for randomization strata
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and significantly higher in the 1,000-1,499 g (p = 0.0003)
and ≥2,500 g groups (p = 0.0078).
Conceding that our gestational age data were not opti-
mal, we nevertheless attempted to evaluate and compare
stillbirth rates by whether the fetuses in the intervention
and control clusters were preterm or term. When the ba-
bies were divided into term and preterm groups, stillbirth
rates were lower but not significantly so in births classified
as preterm (116.6 vs 127.8 per 1000 births (RR 0.93, 95 %
CI 0.83, 1.04, p = 0.182) (Table 2) and significantly higher
in births classified as term in the treatment vs control
clusters, 12.8 vs 10.6 per 1000 births (RR 1 · 20, 95 % CI
1 · 06, 1 · 37, p = 0.004).
Considering these three analyses, the most consistent
finding was a higher rate of stillbirth in the heavier, and
most likely term fetuses in the intervention clusters. The
results for the lighter less mature infants were inconsist-
ent, but some of the results suggest that there may have
been a small reduction in stillbirths in some of the low
birth weight and preterm groups in the intervention
clusters.
We compared the maceration status of the stillbirths by
treatment group (Table 2). Over one third of stillbirths
(35.8 %) in the treatment and 30.5 % in the control group
were macerated. When we modeled macerated status
among the stillbirths, we found that the intervention
cluster stillbirths were significantly more likely to be mac-
erated (RR 1.18, 95 % CI 1.04, 1.35, p = 0.013). In every
percentile group, birth weight group and gestational age
group, maceration was more common in the intervention
clusters while fresh stillbirths were more common in the
control clusters (Table 3).
We also explored when the stillbirths occurred in rela-
tionship to the timing of the first ACS injection, but had
this information only for the intervention clusters. Table 2
shows that half of the mothers of stillbirths who received
ACS delivered within the first week after the ACS injection,
(31 % at <2 days) with about a quarter of the deliveries each
occurring at 8–28 days and > 28 days. Thus, many of the
mothers of stillbirths delivered in relatively close proximity
to receiving the ACS dose. Conversely, about half delivered
a week or more after the ACS administration.
We evaluated various measures of care in the interven-
tion and control clusters, both in the pretrial period and
during the trial in an attempt to discover whether differ-
ences in care or changes in care during the intervention
period might explain part of the difference in stillbirth
rates between the intervention and control clusters. Be-
cause we had pretrial registry data, we were able to evalu-
ate if differences in care observed during the trial predated
the trial. To sum up the data presented in Table 4, there
were differences in the prenatal care and obstetric care
between the intervention and control clusters. Women in
the intervention clusters were more likely to be attended
by nurses during delivery than those in the control clusters
(38 % vs. 30 %) and less likely to be attended by physicians
(39.7 % vs. 45.1 %). More women in the intervention clus-
ters than in the control clusters delivered in clinics (28.2 %
vs. 22.7 %), and fewer had hospital deliveries (49.4 % vs.
53.1 %). Similar patterns were also seen in women with
Table 3 Macerated and non-macerated stillbirths by ACT inter-
vention group
Total
Characteristic, N (%) Intervention Control
All stillbirths, N 1,304 1,264
Maceration 467 (35.8) 385 (30.5)
No maceration 837 (64.2) 879 (69.5)
Birth weight percentilea
< 5th 601 612
Maceration 251 (41.8) 222 (36.3)
No maceration 350 (58.2) 390 (63.7)
5–24 161 139
Maceration 54 (33.5) 38 (27.3)
No maceration 107 (66.5) 101 (72.7)
25–49 110 102
Maceration 28 (25.5) 22 (21.6)
No maceration 82 (74.5) 80 (78.4)
50–74 83 74
Maceration 21 (25.3) 12 (16.2)
No maceration 62 (74.7) 62 (83.8)
75+ 105 87
Maceration 20 (19.0) 11 (12.6)
No maceration 85 (81.0) 76 (87.4)
Birth weight categorizedb
< 1000 g 161 197
Maceration 70 (43.5) 71 (36.0)
No maceration 91 (56.5) 126 (64.0)
1000–1499 g 272 215
Maceration 122 (44.9) 82 (38.1)
No maceration 150 (55.1) 133 (61.9)
1500–2499 g 360 365
Maceration 139 (38.6) 127 (34.8)
No maceration 221 (61.4) 238 (65.2)
2500+ g 466 441
Maceration 116 (24.9) 94 (21.3)
No maceration 350 (75.1) 347 (78.7)
Preterm 645 681
Maceration 258 (40.0) 226 (33.2)
No maceration 387 (60.0) 455 (66.8)
aSite-specific birth weight percentile (measured and estimated
weights combined)
bBirth weight (measured and estimated weights combined)
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<5th percentile infants. These trends were similar to those
noted in the pretrial period. Thus, although there were
differences in care between the intervention and control
clusters during the ACT trial, these differences preceded
the trial. Therefore, we cannot rule out that differences in
care were associated with the higher stillbirth rate in the
intervention clusters.
We did not have data to evaluate whether fetal infection
was more common in stillbirths in the control or interven-
tion clusters since autopsies or placental examinations were
not performed. However, as in the primary paper, we had
data to evaluate potential infection in the mothers. Sus-
pected maternal infection was reported in 2.5 % of women
in the intervention clusters and 1.7 % in the control clusters
(OR 1 · 45, 95 % CI 1 · 33–1 · 58, p < 0 · 0001). Among
women who delivered <5th percentile infants, the suspected
maternal infection was reported in 10.0 % of the women in
the intervention clusters and 6.4 % of women in the control
clusters (OR 1 · 67, 95 % CI 1 · 33–2 · 09, p < 0 · 0001). Thus,
there appeared to be a greater incidence of maternal infec-
tion in the intervention clusters.
Mothers of stillbirths were also more likely to be classi-
fied as having a suspected maternal infection (207/2,526
(8.2 %) versus 1,867/97,211 (1.9 %) of mothers with a live
birth. Among mothers with stillbirth, 114/1,280 (8.9 %) in
the treatment group and 93/1,153 (7.5 %) in the control
group experienced suspected maternal infection. Three of
the sites (Argentina [12.0 % vs 6.7 %], Belgaum [7.8 %
versus 5.3 %] and Nagpur [11.7 % vs 5.0 %] showed mod-
est higher risk of having a suspected maternal infection in
the treatment arm. The other four sites had less than a
1.2 % difference in risk between the arms withGuatemala
and Kenya having slightly higher risk in the treatment arm
and Zambia and Pakistan having slightly higher risk in the
control arm. Because the number of events was relatively
small and all sites had heterogeneity of effects across
randomization strata, no formal inference of overall or
within site differences was conducted and an overall odds
ratio was not calculated.
Finally, we tried to determine if the increase in stillbirth
could be related to the receipt of ACS. In the intervention
clusters, the mothers of 293/1,267 stillbirths (23.2 %)
Table 4 Factors related to process of care by ACT intervention group among all births
Characteristic Pretrial Period Trial Period
Intervention Control Intervention Control
Deliveries, N 30,492 34,533 48,219 51,523
Antenatal Care
Any antenatal care 28,743 (94.4) 32,801 (95.1)
Number of antenatal visits Data not collected during pretrial period 45,374 48,052
0 1,216 (2.7) 1,111 (2.3)
> 3 24,663 (54.4) 25,491 (53.0)
Trimester of 1st antenatal visit 43,980 46,632
1st 22,196 (50.5) 24,801 (53.2)
2nd 14,648 (33.3) 14,059 (30.1)
3rd 7,136 (16.2) 7,772 (16.7)
Administration of diagnosis tests or preventive care
Syphilis or HIV test 21,944/30,435 (72.1) 24,071/34,446 (69.9) 37,975/47,961 (79.2) 40,343/51,185 (78.8)
Tetanus toxoid vaccine 26,892/30,422 (88.4) 30,467/34,478 (88.4) 40,313/47,980 (84.0) 44,453/51,219 (86.8)
Prenatal vitamin/iron 27,706/30,405 (91.1) 30,829/34,472 (89.4) 44,321/47,952 (92.4) 47,212/51,191 (92.2)
Delivery care
Delivery attendant 30,490 34,531 48,215 51,519
Physician 10,305 (33.8) 12,709 (36.8) 19,122 (39.7) 23,233 (45.1)
Nurse/nurse midwife/LHW 10,348 (33.9) 10,094 (29.2) 18,166 (37.7) 15,366 (29.8)
TBA/Family/Unattended 9,837 (32.2) 11,728 (34.0) 10,927 (22.7) 12,920 (25.1)
Delivery location 30,482 34,494 48,217 51,519
Hospital 12,013 (39.4) 15,008 (43.5) 23,798 (49.4) 27,345 (53.1)
Clinic 8,486 (27.8) 7,619 (22.1) 13,593 (28.2) 11,675 (22.7)
Home/Other 9,983 (32.8) 11,867 (34.4) 10,826 (22.5) 12,499 (24.3)
C-section 3,001 (9.8) 3,279 (9.5) 7,133/48,218 (14.8) 7,655/51,520 (14.9)
Goldenberg et al. Reproductive Health  (2016) 13:68 Page 7 of 10
received ACS while in the control clusters, the mothers of
23/1,237 stillbirths (1.9 %) received ACS (Table 5). In the
intervention clusters, fetuses whose mothers received
ACS had more than twice the stillbirth rate compared to
those who did not (51.1 vs 24.3 per 1,000 births). In the
control clusters, the stillbirth rate for babies whose
mothers received ACS was more similar to those who did
not (29.2 vs 25.4 per 1,000 births). Thus, while maternal
receipt of ACS in the intervention clusters was associated
with a doubling of the stillbirth rate, in the control clusters
the increase in stillbirth rate among those fewer women
who received ACS, while still in the same direction, was
not as great as in the intervention clusters. Nevertheless,
with the mothers of 23.5 % of stillbirths receiving ACS,
more than enough women received ACS to potentially ac-
count for the higher stillbirth rate in the intervention
clusters.
Discussion
We explored potential reasons for the higher stillbirth
rate in the intervention clusters compared to the control
clusters in the ACT trial. As a secondary analysis of a
non-primary outcome in a trial not designed for this
purpose, the results cannot be considered definitive, but
may suggest further research directions.
The higher stillbirth rate in intervention clusters was
found in five of the seven sites. Although the overall differ-
ences in stillbirth rates between the intervention and con-
trol clusters were significant, the results were not in the
same direction at all sites. Further exploration of the rea-
sons for site-specific differences in stillbirth rates therefore
may be warranted. Stillbirth rates were higher in the inter-
vention clusters to the same degree in male and female
fetuses so differential impact by gender does not appear to
be part of the explanation for these findings. The increase
in stillbirths occurred in fetuses labeled as macerated and
not in fresh stillbirths. This finding suggests that the higher
stillbirth rate in the intervention clusters did not occur
during the labor and delivery process, but instead occurred
in the antenatal period. Since about 50 % of the mothers of
stillbirths delivered within a week after receiving the ACS
injection, this suggests, but does not prove, that some of
the increase in stillbirths associated with being in the inter-
vention clusters occurred within days after receiving the
ACS injection, but not during labor. On the other hand,
about 50 % of the mothers of stillbirths delivered more than
a week following receipt of ACS.
Because of the relatively poor gestational age ascertain-
ment at the sites during the trial, the results regarding
gestational age and stillbirth rates should be interpreted
cautiously. Nevertheless, the stillbirth rate was higher in the
intervention clusters in fetuses who appeared to be term
compared to preterm, in fetuses ≥25th percentile birth
weight, and in fetuses ≥ 2500 g. These consistent results
strongly suggest that there were higher stillbirth rates in the
heavier more mature fetuses in the intervention clusters.
The results for the smaller and earlier gestational age
fetuses are less consistent. Since there were fewer stillbirths
in the intervention clusters in the < 5th percentile births, in
the < 1000 g births and in the 1500 to 2499 g births and in
fetuses categorized as preterm, it is unlikely the interven-
tion was associated with a higher stillbirth rate in smaller
earlier gestational age stillbirths, and there may have been a
small reduction in the stillbirth rates in these groups.
The reason mothers of fetuses who received ACS deliv-
ered outside the targeted window or even at term are
Table 5 Stillbirth rates by ACS administrationa and ACT intervention group and site
Argentina Guatemala Pakistan Belgaum

















Deliveries, N 271 1,297 163 1,551 540 5,135 39 3,812 1,871 5,927 125 8,186 1,743 13,228 332 16,407
Stillbirths, N 5 18 3 24 12 94 0 69 117 271 4 347 80 296 4 377
Stillbirths≥ 20 weeks GA































Nagpur Kenya Zambia Total

















Deliveries, N 612 5,822 84 6,351 178 5,708 30 7,007 519 3,043 15 4,550 5,734 40,160 788 47,864
Stillbirths, N 36 110 5 164 16 123 5 148 27 62 2 85 293 974 23 1,214
Stillbirths≥ 20 weeks GA

































aData on administration of ACS from the MNH Registry are available for 1,267/1,304 (97.2 %) of stillbirths in the intervention group and 1,237/1,264 (97.9 %) of
stillbirths in the control group
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unknown. One possible explanation is that the gestational
age dating was often inaccurate, and the care givers who
determined use of ACS were often inexperienced and
poorly trained. Another explanation, and a common finding
in many of the published ACS trials, is that a significant
proportion of ACS recipients were in the appropriate gesta-
tional age interval when they received the ACS injection,
but delivered later in their pregnancy [11, 12]. We expect
that both explanations account for the fact that many
women in this trial who received ACS delivered heavier
and older gestational age infants.
We have little data to help us explain the cause for the
higher stillbirth rate in the intervention clusters. From
the primary paper we know that women in the interven-
tion arm likely had more infections than women and
neonates in the control clusters [2]. We also know that
the increase in stillbirths in the intervention compared
to control clusters was associated with a higher rate of
maceration, suggesting that asphyxia during labor was
not the cause of the higher stillbirth rate. Since aside
from asphyxia and congenital anomalies, infection is the
primary cause of stillbirths, it is conceivable that the
higher rate of stillbirths associated with being in the
intervention clusters is in part related to increased infec-
tion. Proving that this is the explanation for the higher
rate of stillbirths in the intervention clusters is not pos-
sible from the available data, but any future study of
ACS in LIC settings should collect data related to mater-
nal and fetal infection status.
There were differences in obstetric care between the
intervention and control clusters and these differences
were found in both the pretrial and trial period. In the
pretrial period these differences were also associated
with a difference in stillbirth rates between the interven-
tion and control clusters. Therefore, our data do not
allow us to rule out the possibility that part of the differ-
ences in stillbirth rates between the intervention and
control clusters prior to and during the trial were due to
differences in obstetric care.
Most randomized trials of ACS have not reported still-
birth rates and those that have reported stillbirth rates
generally report stillbirths that occurred in the week
following ACS administration or in preterm newborns.
However, a meta-analysis of women who received ACS
and delivered later than 7 days after ACS administration
showed significant increases in both perinatal deaths and
in chorioamnionitis in the treatment group [13]. Stillbirths
were increased, but not significantly so. Thus, there is a
precedent in the literature that ACS given to women who
ultimately deliver outside the one-week window of likely
benefit for neonatal outcomes may have an increase in in-
fection and stillbirth associated with ACS administration.
Because so many women in this trial delivered outside the
7-day window, and delivered more mature and heavier
infants, these factors may explain some of the ACT study
stillbirth findings. However, more likely, the differences in
stillbirth rates between the intervention and control clus-
ters in the ACT trial period are explained at least in part
by the differences in health care that existed prior to the
ACT study and continued throughout the study.
Conclusions
In summary, in the ACT trial there was a small but signifi-
cantly higher rate of stillbirths among women in the inter-
vention clusters. The increase was seen in 5 of the 7 sites,
and was not consistent across the study. Differences in care
between the intervention and control clusters may explain
part or all of the higher stillbirth rate in the intervention
clusters, but this possibility cannot be proven from the
available data. It is also possible that differences in unmeas-
ured maternal characteristics such as syphilis or malaria
played a role. The higher stillbirth rate in the intervention
clusters was similar in male and female fetuses. The higher
stillbirth rate in the intervention clusters was apparent only
in the larger and term fetuses. There was no consistent
increase in stillbirths in the intervention clusters in the
lighter more preterm infants and there may have been a
small reduction in stillbirths in some birth weight and
gestational age groups. Because of the poor gestational age
dating available for those participating in the ACT trial, we
can make no definitive statement about the impact of the
intervention on stillbirth rates in smaller and earlier gesta-
tional age fetuses. Finally, data related to causation are lim-
ited, but suggest that fetal asphyxia is not likely to explain
our findings. Instead, our data suggest that infection may
explain some of the observed higher rate of stillbirths in the
intervention clusters. The meta-analysis of individually ran-
domized ACS trials showing an increase in infection and
perinatal mortality in women delivering more than 7 days
after receiving ACS lends credence to this hypothesis [10].
Nevertheless, it appears that the higher stillbirth rate in the
intervention clusters preceded the study and was coincident
with differences in obstetric care between the intervention
and control clusters. We also emphasize that the difference
in stillbirth rates between the intervention and control clus-
ters was small and although statistically significant could
have occurred by chance.
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